LakeShore Biopharma (LSB) Stock Analysis

What LakeShore Biopharma does

LakeShore Biopharma Co., Ltd is a biopharmaceutical firm focused on the discovery, advancement, manufacturing, and marketing of vaccines and therapeutic biologics. Its primary targets are infectious diseases and various forms of cancer. At the core of its innovation is a proprietary PIKA immunomodulating technology platform, which underpins its product pipeline, featuring a PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. The company maintains an international presence, conducting operations across China, the United States, Singapore, the United Arab Emirates, and the Philippines. Originally founded in 2002 and based in Beijing, China, the entity was known as YS Biopharma Co., Ltd until it officially changed its name to LakeShore Biopharma Co., Ltd in May 2024.

Key metrics

ETFs linked to LSB

Broad-market and Healthcare sector ETFs an investor holding LakeShore Biopharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LSB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for LakeShore Biopharma?

LakeShore Biopharma trades under the ticker LSB on NASDAQ.

Which exchange is LSB listed on?

LSB is listed on NASDAQ.

What sector does LakeShore Biopharma operate in?

LakeShore Biopharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze LSB in a portfolio?

PortView shows LSB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.